Physician profile
Vincent Caicco
NPI 1932506730
$3,379.59
in general payments reported to CMS, 2019-2025
21 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.97 · 2022: $633 · 2023: $1,140 · 2024: $974 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $571.56 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $458.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $426.56 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $356.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $276.69 | 2022-2025 | |
| Glaxosmithkline, LLC. | $238.35 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $193.24 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $142.85 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $128.06 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.83 | 2022-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $82.03 | 2022-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $71.49 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $53.69 | 2023-2024 | |
| Exact Sciences Corporation | $52.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $52.31 | 2023-2024 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.58 | 2022-2023 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $33.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.46 | 2022 | |
| Ibsa Pharma INC. | $19.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.91 | 2022 | |
| Horizon Therapeutics Plc | $16.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Caicco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.